Articles by Shim Woo-hyun
Shim Woo-hyun
ws@heraldcorp.com-
Celltrion partners with US pharmacy chain for Yuflyma sales
Celltrion Healthcare, Celltrion's distribution unit, said Monday it has signed a deal with US specialty pharmacy chain CarePartners Pharmacy to sell its Humira biosimilar Yuflyma in the US market. CarePartners Pharmacy is a national pharmacy that distributes medications across all 50 states and Washington DC, focusing on several niche programs, including autoimmune therapies. Under the contract, Yuflyma will be distributed to drug stores operated by CarePartners Pharmacy nationwide, startin
Industry Oct. 16, 2023
-
S. Korea may decide to increase medical student quota as early as next week
The South Korean government may announce its plan to increase the medical school enrollment quota as early as next week, according to local reports Friday. The government is reportedly reviewing a plan to increase the medical school enrollment quota by 500, from the current quota of 3,058, which has remained unchanged since 2006. If expanded, the new quota will be applied starting in 2025. Minister of Health and Welfare Cho Kyu-hong also said, “We are preparing to reflect it in the 2025 co
Industry Oct. 13, 2023
-
KT & G to build new tobacco plant in Kazakhstan
KT&G, South Korea's largest tobacco company, said Thursday that the company has started construction of its fourth overseas manufacturing plant in Kazakhstan. The new plant will be built on a 200,000-square-meter site and is scheduled to be completed by 2025. The company did not disclose how much it would invest in the construction of the Kazakhstan plant. “We expect the new Kazakhstan factory to serve as a core global production hub that encompasses the Eurasian market," said KT
Industry Oct. 12, 2023
-
Posco Holdings recoups investment in Roy Hill after 13 years
Posco Holdings said on Tuesday the company has received 85 billion won ($62 million) in dividends from the third quarter earnings of Roy Hill Holdings, recouping the investment it has made into the holding company of Australian iron ore miner Roy Hill. With the latest dividend payment, Posco Holdings has received a total of 1.3 trillion won in total in the form of dividends and discounts on iron ore that the company imported from Australia, retrieving 1.3 trillion won of investment it made to ac
Industry Oct. 10, 2023
-
Asiana may ditch cargo business to close Korean Air merger deal
Asiana Airlines is expected to discuss selling its cargo business as part of Korean Air’s new merger plan, which is facing antitrust concerns in Europe, according to industry sources, Sunday. Sources said the agenda is highly likely to be discussed at a board meeting at the end of the month. Asiana Airlines' potential disposal of its cargo business comes as Korean Air plans to submit an amended merger plan with the smaller rival to the European Commission later this month. The Europ
Industry Oct. 8, 2023
-
Lotte Biologics doubles down on global contract drugmaker ambitions
Lotte Biologics is gearing up for the construction of three drug manufacturing plants with its recent land purchase in Songdo, Incheon, taking its first step on its decadelong journey to become a global contract development and manufacturing organization. Lotte Biologics said the company signed a land purchase agreement with the Incheon Free Economic Zone Authority on Wednesday afternoon. Under the agreement, Lotte Biologics will build three biomanufacturing facilities. Each plant is going to ha
Industry Oct. 5, 2023
-
Celltrion's Humira biosimilar receives FDA approval for new doses
Celltrion announced Wednesday that the company received approval from the US Food and Drug Administration for two more dose versions of its Humira biosimilar Yuflyma, for 20 and 80 milligrams. Yuflyma is a copycat version of AbbVie’s blockbuster drug Humira, used to treat many inflammatory conditions in adults such as rheumatoid arthritis and psoriatic arthritis. With the FDA’s latest approval, Celltrion is now able to sell three different dose versions of Yuflyma in the US. The 40 m
Industry Oct. 4, 2023
-
Samsung Biologics raises annual estimated earnings to W3.6t
Samsung Biologics has raised the full-year earnings estimate in its company guidance again to 3.6 trillion won ($2.6 billion) for this year, up some 20 percent from last year, according to its regulatory filing released on Wednesday. It was the second time this year for Samsung Biologics to increase the estimate of its annual earnings. Earlier in April, the company raised its estimated earnings from sales to 3.52 trillion won. “(Samsung Biologics) has readjusted (the estimated earnings in
Industry Oct. 4, 2023
-
House ownership widens wealth gap between young and old
The wealth gap between younger and older adults has widened over the last few years, largely depending on whether they own houses or not, according to the country’s statistics agency, Wednesday. According to the Statistics Korea’s report, the wealth gap between adults aged 40 and above and adults younger than 40 has widened by 45 percent over the last three years, from 160 million won ($118,000) in 2019 to 230 million won in 2022. Kim Mee-roo, a researcher at the Korea Development In
Industry Sept. 27, 2023
-
Asiana mishandled midair door-opening, ministry rules
Asiana Airlines’ initial response to a recent midair door-opening incident was "inappropriate" and will be fined for it, the South Korean government's investigation showed, Rep. Park Sang-hyuk of the main opposition Korea Democratic Party said Wednesday. According to a report Park received from the Ministry of Land, Infrastructure and Transport, the ministry has imposed a fine on Asiana Airlines and recommended country’s second largest air carrier take corrective actio
Industry Sept. 27, 2023
-
Samsung Biologics attends CSLA investor forum
Samsung Biologics said Monday the company participated in CSLA's flagship investor forum which was held in Hong Kong on Sept. 11-14, to promote the company’s vision and business strategy. The investors’ forum, one of the largest of its kind in Asia, is held by CLSA, an institutional broker and investment group owned by CITIC Securities. Around 400 Asian companies and some 3,000 people from the industry joined the latest edition of the forum. Samsung Biologics was the only Korean
Industry Sept. 25, 2023
-
Incheon Airport passenger traffic to recover during Chuseok holiday
Tourism during South Korea’s Thanksgiving holiday of Chuseok is expected to rebound to pre-COVID-19 levels, industry sources said Sunday. According to Incheon Airport, the number of passengers who will be using the country's main gateway between Sept. 27 and Oct. 3 is expected to reach 1.2 million, an average of about 170,000 each day. The number has also recovered to 96.6 percent of the corresponding figure in 2019. The figure is also up by 186.7 percent compared to the previous ye
Industry Sept. 24, 2023
-
SPC Samlip to showcase K-desserts at int'l food fair
South Korean confectionery company SPC Samlip has joined global food trade fair Anuga to promote Korean dessert products, the company said Thursday. Anuga is an annual food trade fair held in Cologne, Germany. This year’s edition will run between Oct. 7-11, featuring around 8,000 companies from 100 countries. During the fair, which will attract over 100,000 visitors, SPC Samlip will introduce its 53 products, ranging from yakgwa (deep-fried honey cookies) to hotteok (sweet pancakes with br
Industry Sept. 21, 2023
-
[Herald Interview] Next & Bio aims to build Asia’s largest library of organoids
South Korean biotech company Next & Bio, which specializes in developing organoid-based medicine solutions, aims to build the largest organoid library in Asia, its CEO told The Korea Herald in a recent interview. Organoids are cell-based in vitro models that mimic many aspects of the complex structure and function of the corresponding human organs. Organoid-based systems have been recently spotlighted as alternatives to animal experimentation in clinical research and precision medicine. &ldq
Industry Sept. 21, 2023
-
Samsung Biologics stands tall among pharma giants
South Korean biopharmaceutical company Samsung Biologics said Wednesday that the company achieved a stellar performance last year to stand shoulder to shoulder with top global pharmaceutical companies, buoyed by an array of large contract manufacturing deals. The company has been ranked in 37th place in market research company GlobalData’s list of the world's top 50 pharmaceutical companies in 2022, up 13 spots from 2021. According to the rankings, which listed companies based on thei
Industry Sept. 19, 2023
Most Popular
-
1
[Exclusive] Korean military set to ban iPhones over 'security' concerns
-
2
Korean, Romanian leaders discuss defense tech, nuclear energy
-
3
S. Korea calls on Japan to confront history amid Yasukuni Shrine visit
-
4
Yoon’s jailed mother-in-law excluded from latest parole list
-
5
Hybe and Min Hee-jin, CEO of Hybe sublabel Ador, lock horns
-
6
[Pressure points] Leggings in public: Fashion statement or social faux pas?
-
7
[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'
-
8
Korea’s homegrown nanosatellite successfully launches into space
-
9
Nicaragua shuts down Seoul embassy
-
10
Rocket engine expert, ex-NASA exec to lead Korea's new space agency